Iowanews Headlines

The Growth Hormone Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Growth Hormone Deficiency market dynamics.

DelveInsight’s “Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Growth Hormone Deficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Growth Hormone Deficiency Market Forecast

Some of the key facts of the Growth Hormone Deficiency Market Report:

• In 2023, the Growth Hormone Deficiency market across the 7MM was estimated to be worth around USD 1.4 billion. Between 2025 and 2034, the market is expected to expand at a compound annual growth rate (CAGR) of 5.7%.

• In November 2025, Ascendis Pharma A/S (Nasdaq: ASND) reported SKYTROFA revenues of €50.7 million for Q3 2025, reflecting a €1.6 million negative impact from foreign exchange compared to the previous quarter. The company also received FDA approval for the first label expansion of SKYTROFA for adult growth hormone deficiency, marking the initial step among several anticipated future label extensions.

• In July 2025, Ascendis Pharma A/S (Nasdaq: ASND) announced that the FDA has approved SKYTROFA® (lonapegsomatropin-tcgd; also known as TransCon hGH) for adults with growth hormone deficiency (GHD), a rare condition caused by reduced or absent growth hormone production. Previously approved in 2021 for pediatric GHD, lonapegsomatropin is a once-weekly prodrug of somatropin that delivers a sustained release of the active, unmodified human growth hormone.

• In May 2025, Specialised Therapeutics (ST), an independent biopharmaceutical company, has announced that SKYTROFA® (lonapegsomatropin) has been officially registered in Australia as a once-weekly injectable treatment for pediatric growth hormone deficiency (GHD). The Therapeutic Goods Administration (TGA) has approved SKYTROFA for the treatment of growth failure in children and adolescents aged 3 to 18 years caused by insufficient natural growth hormone production.

• In December 2024, JCR Pharmaceuticals (TSE 4552) announced the dosing of the first participant in its Phase III trial of JR-142 (redalsomatropin alfa) in Japan, marking a key advancement in the therapy’s development. JR-142, a long-acting growth hormone treatment, is being evaluated in children with pediatric growth hormone deficiency. The study will enroll 54 pediatric patients and compare JR-142 against JCR’s current therapy, Growject®, over a 52-week treatment period, with growth improvement as the primary endpoint. Further details are available on the Japan Register of Clinical Trials (jRCT2031240282).

• In 2023, the Growth Hormone Deficiency market in the United States was valued at around USD 873.4 million and is expected to grow further with the introduction of upcoming therapies.

• In 2023, the combined market size of the EU4 and the UK was estimated at around USD 370.2 million, accounting for nearly 27% of the total revenue across the 7MM.

• In 2023, Germany led the Growth Hormone Deficiency market within the EU4 and the UK, with revenue of approximately USD 96.5 million. The UK came next with around USD 86.2 million, followed by France at roughly USD 82.0 million.

• In 2023, Japan’s total market size for Growth Hormone Deficiency was estimated at around USD 137.0 million, with expectations of growth throughout the forecast period (2025–2034).

• Projections indicate that LUM-201 is anticipated to generate around USD 131.1 million in revenue across the 7MM by 2034.

• In 2024, growth hormone deficiency impacted approximately 207,000 people across the 7MM, and this figure is expected to rise steadily by 2034, highlighting the increasing burden of the condition and the growing necessity for enhanced diagnostic and treatment methods.

• According to DelveInsight’s estimates, approximately 33,000 diagnosed prevalent cases of pediatric growth hormone deficiency (pGHD) were recorded in the 7MM in 2024. This reflects the condition’s rarity while outlining a specific patient pool suitable for focused treatment development.

• In 2024, the United States reported roughly 17,000 diagnosed prevalent cases of pGHD, the highest within the 7MM. This leading share underscores substantial clinical need and a strong market potential in the US healthcare sector.

• In 2024, the diagnosed prevalent population of pGHD across the EU4 nations and the UK was estimated to be around 12,000 individuals.

• In 2024, Japan recorded an estimated 4,400 diagnosed prevalent cases of pediatric growth hormone deficiency.

• Key Growth Hormone Deficiency Companies: Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others

• Key Growth Hormone Deficiency Therapies: SOGROYA (somapacitan-beco), SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd), LUM-201 (ibutamoren), SCO-240, and others

• The Growth Hormone Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Growth Hormone Deficiency pipeline products will significantly revolutionize the Growth Hormone Deficiency market dynamics.

Growth Hormone Deficiency Overview

Growth Hormone Deficiency (GHD) is a medical condition in which the body doesn’t produce enough growth hormone, a key hormone responsible for growth, cell repair, and metabolism. It can occur in both children and adults. In children, GHD leads to slowed growth and short stature, while in adults, it may cause fatigue, reduced muscle mass, increased fat, and poor bone density. Causes can include genetic disorders, brain injuries, or tumors. Treatment typically involves daily injections of synthetic growth hormone to restore normal growth and metabolic function.

Request a sample for the Growth Hormone Deficiency Market Report:

https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market

Growth Hormone Deficiency Epidemiology

The Growth Hormone Deficiency epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Growth Hormone Deficiency Epidemiology Segmentation:

The Growth Hormone Deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of GHD in the 7MM

• Total Diagnosed Prevalent Cases of GHD in the 7MM

• Diagnosed Prevalent Cases of pGHD in the 7MM

• Treated Cases of pGHD in the 7MM

Download the report to understand which factors are driving Growth Hormone Deficiency epidemiology trends @ Growth Hormone Deficiency Epidemiological Insights

Growth Hormone Deficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Growth Hormone Deficiency market or expected to get launched during the study period. The analysis covers Growth Hormone Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Growth Hormone Deficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Growth Hormone Deficiency Therapies and Companies

• Novo Nordisk: SOGROYA (somapacitan-beco)

• Ascendis Pharma: SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd)

• Double Point Ventures (Lumos Pharma): LUM-201 (ibutamoren)

• SCOHIA PHARMA: SCO-240

To know more about Growth Hormone Deficiency treatment, visit @ Growth Hormone Deficiency Medications

Growth Hormone Deficiency Market Strengths

• Various approved therapies are available in the market for this condition which can help in successfully treating PGHD.

• The emerging pipeline has some very potential treatments for PGHD.

Growth Hormone Deficiency Market Opportunities

• Since the emerging and approved treatments mainly comprise of long-acting hGH, this is a major opportunity for companies to develop novel drugs with innovative mechanism of action for PGHD which will give them an edge in the current market.

Scope of the Growth Hormone Deficiency Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Growth Hormone Deficiency Companies: Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others

• Key Growth Hormone Deficiency Therapies: SOGROYA (somapacitan-beco), SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd), LUM-201 (ibutamoren), SCO-240, and others

• Growth Hormone Deficiency Therapeutic Assessment: Growth Hormone Deficiency current marketed and Growth Hormone Deficiency emerging therapies

• Growth Hormone Deficiency Market Dynamics: Growth Hormone Deficiency market drivers and barriers

• Growth Hormone Deficiency Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Growth Hormone Deficiency Unmet Needs, KOL’s views, Analyst’s views, Growth Hormone Deficiency Market Access and Reimbursement

Discover more about therapies set to grab major Growth Hormone Deficiency market share @ Growth Hormone Deficiency Treatment Landscape

Table of Contents

1. Growth Hormone Deficiency Market Report Introduction

2. Executive Summary for Growth Hormone Deficiency

3. SWOT analysis of Growth Hormone Deficiency

4. Growth Hormone Deficiency Patient Share (%) Overview at a Glance

5. Growth Hormone Deficiency Market Overview at a Glance

6. Growth Hormone Deficiency Disease Background and Overview

7. Growth Hormone Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Growth Hormone Deficiency

9. Growth Hormone Deficiency Current Treatment and Medical Practices

10. Growth Hormone Deficiency Unmet Needs

11. Growth Hormone Deficiency Emerging Therapies

12. Growth Hormone Deficiency Market Outlook

13. Country-Wise Growth Hormone Deficiency Market Analysis (2020–2034)

14. Growth Hormone Deficiency Market Access and Reimbursement of Therapies

15. Growth Hormone Deficiency Market drivers

16. Growth Hormone Deficiency Market barriers

17. Growth Hormone Deficiency Appendix

18. Growth Hormone Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/